[96a5a0]: / output / allTrials / identified / NCT03952065_identified.json

Download this file

721 lines (721 with data), 30.4 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
{
"info": {
"nct_id": "NCT03952065",
"official_title": "A Phase II/III Randomized Trial of Comparison of Survival Benefit of Administration of PD1/PDL1/CTLA4 Inhibitors or Their Combinations Via Neck Artery or Intratumor Versus Vein Infusion for Immunotherapy of HNC",
"inclusion_criteria": "1. Cytohistological confirmation is required for diagnosis of HNC.\n2. Signed informed consent before recruiting.\n3. Age between 18 to 80 years with estimated survival over 3 months.\n4. ECOG score < 2\n5. Tolerable coagulation function or reversible coagulation disorders\n6. Laboratory examination test within 7 days prior to procedure: WBC≥3.0×10E9/L; Hb≥90g/L; PLT ≥50×10E9/L;INR < 2.3 or PT < 6 seconds above control;Cr ≤ 145.5 umul/L;Albumin > 28 g/L;Total bilirubin < 51 μmol/L\n7. At least one tumor lesion meeting measurable disease criteria as determined by RECIST v1.1.\n8. Patients with advanced HNC which would not be suitable for treatment with loco-regional therapies or have progressed following locoregional therapy such as surgical resection and other treatment.\n9. Birth control.\n10. Willing and able to comply with scheduled visits, treatment plan and laboratory tests.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
"exclusion_criteria": "1. Patients participated in other clinical trials of equipment or drugs (signed informed consent) within 4 weeks;\n2. Any serious accompanying disease, which is expected to have an unknown, impact on the prognosis, include heart disease, inadequately controlled diabetes and psychiatric disorders;\n3. Patients accompanied with other tumors or past medical history of malignancy;\n4. Pregnant or lactating patients, all patients participating in this trial must adopt appropriate birth control measures during treatment;\n5. Patients have poor compliance.\n\n Any contraindications for neck artery infusion procedure:\n\n A. Impaired clotting test (platelet count < 60000/mm3, prothrombin activity < 50%).\n\n B. Renal failure / insufficiency requiring hemo-or peritoneal dialysis. C. Known severe atheromatosis. D. Known uncontrolled blood hypertension (> 160/100 mm/Hg).\n6. Allergic to adriamycin chemotherapy drugs,contrast agent or lipiodol;\n7. Any agents which could affect the absorption or pharmacokinetics of the study drugs\n8. Subjects unable to suffer the discomfort of the artery infusion procedure",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "1. Cytohistological confirmation is required for diagnosis of HNC.",
"criterions": [
{
"exact_snippets": "Cytohistological confirmation is required for diagnosis of HNC.",
"criterion": "cytohistological confirmation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "diagnosis of HNC",
"criterion": "HNC diagnosis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "2. Signed informed consent before recruiting.",
"criterions": [
{
"exact_snippets": "Signed informed consent",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "signed",
"expected_value": true
}
]
}
]
},
{
"line": "3. Age between 18 to 80 years with estimated survival over 3 months.",
"criterions": [
{
"exact_snippets": "Age between 18 to 80 years",
"criterion": "age",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 18,
"unit": "years"
},
{
"operator": "<=",
"value": 80,
"unit": "years"
}
]
}
}
]
},
{
"exact_snippets": "estimated survival over 3 months",
"criterion": "estimated survival",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">",
"value": 3,
"unit": "months"
}
}
]
}
]
},
{
"line": "4. ECOG score < 2",
"criterions": [
{
"exact_snippets": "ECOG score < 2",
"criterion": "ECOG score",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": "<",
"value": 2,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "5. Tolerable coagulation function or reversible coagulation disorders",
"criterions": [
{
"exact_snippets": "Tolerable coagulation function",
"criterion": "coagulation function",
"requirements": [
{
"requirement_type": "tolerance",
"expected_value": "tolerable"
}
]
},
{
"exact_snippets": "reversible coagulation disorders",
"criterion": "coagulation disorders",
"requirements": [
{
"requirement_type": "reversibility",
"expected_value": true
}
]
}
]
},
{
"line": "6. Laboratory examination test within 7 days prior to procedure: WBC≥3.0×10E9/L; Hb≥90g/L; PLT ≥50×10E9/L;INR < 2.3 or PT < 6 seconds above control;Cr ≤ 145.5 umul/L;Albumin > 28 g/L;Total bilirubin < 51 μmol/L",
"criterions": [
{
"exact_snippets": "WBC≥3.0×10E9/L",
"criterion": "WBC",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 3.0,
"unit": "×10E9/L"
}
}
]
},
{
"exact_snippets": "Hb≥90g/L",
"criterion": "Hb",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 90,
"unit": "g/L"
}
}
]
},
{
"exact_snippets": "PLT ≥50×10E9/L",
"criterion": "PLT",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 50,
"unit": "×10E9/L"
}
}
]
},
{
"exact_snippets": "INR < 2.3",
"criterion": "INR",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<",
"value": 2.3,
"unit": "N/A"
}
}
]
},
{
"exact_snippets": "PT < 6 seconds above control",
"criterion": "PT",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<",
"value": 6,
"unit": "seconds above control"
}
}
]
},
{
"exact_snippets": "Cr ≤ 145.5 umul/L",
"criterion": "Cr",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<=",
"value": 145.5,
"unit": "umul/L"
}
}
]
},
{
"exact_snippets": "Albumin > 28 g/L",
"criterion": "Albumin",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">",
"value": 28,
"unit": "g/L"
}
}
]
},
{
"exact_snippets": "Total bilirubin < 51 μmol/L",
"criterion": "Total bilirubin",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<",
"value": 51,
"unit": "μmol/L"
}
}
]
}
]
},
{
"line": "7. At least one tumor lesion meeting measurable disease criteria as determined by RECIST v1.1.",
"criterions": [
{
"exact_snippets": "At least one tumor lesion meeting measurable disease criteria as determined by RECIST v1.1.",
"criterion": "tumor lesion",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "lesion"
}
},
{
"requirement_type": "measurable disease criteria",
"expected_value": "RECIST v1.1"
}
]
}
]
},
{
"line": "8. Patients with advanced HNC which would not be suitable for treatment with loco-regional therapies or have progressed following locoregional therapy such as surgical resection and other treatment.",
"criterions": [
{
"exact_snippets": "advanced HNC",
"criterion": "HNC (head and neck cancer)",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "advanced"
}
]
},
{
"exact_snippets": "not be suitable for treatment with loco-regional therapies",
"criterion": "suitability for loco-regional therapies",
"requirements": [
{
"requirement_type": "suitability",
"expected_value": false
}
]
},
{
"exact_snippets": "have progressed following locoregional therapy",
"criterion": "progression after locoregional therapy",
"requirements": [
{
"requirement_type": "progression",
"expected_value": true
}
]
}
]
},
{
"line": "9. Birth control.",
"criterions": [
{
"exact_snippets": "Birth control",
"criterion": "birth control",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "10. Willing and able to comply with scheduled visits, treatment plan and laboratory tests.",
"criterions": [
{
"exact_snippets": "Willing and able to comply with scheduled visits",
"criterion": "compliance with scheduled visits",
"requirements": [
{
"requirement_type": "willingness",
"expected_value": true
},
{
"requirement_type": "ability",
"expected_value": true
}
]
},
{
"exact_snippets": "Willing and able to comply with ... treatment plan",
"criterion": "compliance with treatment plan",
"requirements": [
{
"requirement_type": "willingness",
"expected_value": true
},
{
"requirement_type": "ability",
"expected_value": true
}
]
},
{
"exact_snippets": "Willing and able to comply with ... laboratory tests",
"criterion": "compliance with laboratory tests",
"requirements": [
{
"requirement_type": "willingness",
"expected_value": true
},
{
"requirement_type": "ability",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 80 Years",
"criterions": [
{
"exact_snippets": "maximum age of 80 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 80,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "1. Patients participated in other clinical trials of equipment or drugs (signed informed consent) within 4 weeks;",
"criterions": [
{
"exact_snippets": "Patients participated in other clinical trials of equipment or drugs (signed informed consent) within 4 weeks",
"criterion": "participation in other clinical trials",
"requirements": [
{
"requirement_type": "time since participation",
"expected_value": {
"operator": "<=",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "2. Any serious accompanying disease, which is expected to have an unknown, impact on the prognosis, include heart disease, inadequately controlled diabetes and psychiatric disorders;",
"criterions": [
{
"exact_snippets": "serious accompanying disease",
"criterion": "serious accompanying disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "heart disease",
"criterion": "heart disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "inadequately controlled diabetes",
"criterion": "inadequately controlled diabetes",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "psychiatric disorders",
"criterion": "psychiatric disorders",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "3. Patients accompanied with other tumors or past medical history of malignancy;",
"criterions": [
{
"exact_snippets": "Patients accompanied with other tumors",
"criterion": "other tumors",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "past medical history of malignancy",
"criterion": "past medical history of malignancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "4. Pregnant or lactating patients, all patients participating in this trial must adopt appropriate birth control measures during treatment;",
"criterions": [
{
"exact_snippets": "Pregnant or lactating patients",
"criterion": "pregnancy status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "not pregnant or lactating"
}
]
},
{
"exact_snippets": "all patients participating in this trial must adopt appropriate birth control measures during treatment",
"criterion": "birth control measures",
"requirements": [
{
"requirement_type": "adoption",
"expected_value": true
}
]
}
]
},
{
"line": "5. Patients have poor compliance.",
"criterions": [
{
"exact_snippets": "Patients have poor compliance.",
"criterion": "compliance",
"requirements": [
{
"requirement_type": "quality",
"expected_value": "poor"
}
]
}
]
},
{
"line": "Any contraindications for neck artery infusion procedure:",
"criterions": [
{
"exact_snippets": "contraindications for neck artery infusion procedure",
"criterion": "neck artery infusion procedure",
"requirements": [
{
"requirement_type": "contraindications",
"expected_value": true
}
]
}
]
},
{
"line": "A. Impaired clotting test (platelet count < 60000/mm3, prothrombin activity < 50%).",
"criterions": [
{
"exact_snippets": "platelet count < 60000/mm3",
"criterion": "platelet count",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<",
"value": 60000,
"unit": "mm3"
}
}
]
},
{
"exact_snippets": "prothrombin activity < 50%",
"criterion": "prothrombin activity",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<",
"value": 50,
"unit": "%"
}
}
]
}
]
},
{
"line": "B. Renal failure / insufficiency requiring hemo-or peritoneal dialysis. C. Known severe atheromatosis. D. Known uncontrolled blood hypertension (> 160/100 mm/Hg).",
"criterions": [
{
"exact_snippets": "Renal failure / insufficiency requiring hemo-or peritoneal dialysis.",
"criterion": "renal failure / insufficiency",
"requirements": [
{
"requirement_type": "treatment",
"expected_value": [
"hemodialysis",
"peritoneal dialysis"
]
}
]
},
{
"exact_snippets": "Known severe atheromatosis.",
"criterion": "atheromatosis",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "severe"
}
]
},
{
"exact_snippets": "Known uncontrolled blood hypertension (> 160/100 mm/Hg).",
"criterion": "blood hypertension",
"requirements": [
{
"requirement_type": "control",
"expected_value": "uncontrolled"
},
{
"requirement_type": "severity",
"expected_value": {
"operator": ">",
"value": 160,
"unit": "mm/Hg"
}
}
]
}
]
},
{
"line": "6. Allergic to adriamycin chemotherapy drugs,contrast agent or lipiodol;",
"criterions": [
{
"exact_snippets": "Allergic to adriamycin chemotherapy drugs",
"criterion": "allergy to adriamycin chemotherapy drugs",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Allergic to ... contrast agent",
"criterion": "allergy to contrast agent",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Allergic to ... lipiodol",
"criterion": "allergy to lipiodol",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "7. Any agents which could affect the absorption or pharmacokinetics of the study drugs",
"criterions": [
{
"exact_snippets": "agents which could affect the absorption or pharmacokinetics of the study drugs",
"criterion": "agents affecting absorption or pharmacokinetics",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "8. Subjects unable to suffer the discomfort of the artery infusion procedure",
"criterions": [
{
"exact_snippets": "unable to suffer the discomfort of the artery infusion procedure",
"criterion": "tolerance to artery infusion procedure",
"requirements": [
{
"requirement_type": "tolerance",
"expected_value": true
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}